摘要
目的探讨沙库巴曲缬沙坦钠片(商品名:诺欣妥)联合达格列净对射血分数降低心力衰竭(心衰)(HFrEF)的治疗效果及安全性。方法60例射血分数降低心衰患者,使用随机数字表法分为观察组与对照组,每组30例。对照组接受诺欣妥治疗,观察组接受诺欣妥联合达格列净治疗。比较两组患者治疗5个月后的心功能[血浆N末端脑钠肽前体(NT-proBNP)、左室射血分数(LVEF)、左室舒张末期内径(LVEDD)、6 min步行试验(6MWT)距离],治疗前后生活质量[明尼苏达心衰生活质量量表(MLHFQ)评分],不良事件发生率。结果治疗后,观察组患者NT-proBNP(865.47±68.41)pg/ml低于对照组的(1285.54±105.84)pg/ml,LVEDD(51.47±3.54)mm短于对照组的(58.65±1.47)mm,LVEF(48.56±10.65)%高于对照组的(38.36±5.34)%,6MWT距离(324.02±40.65)m长于对照组的(226.35±34.91)m,差异具有统计学意义(P<0.05)。治疗后,两组患者MLHFQ评分均较治疗前降低,且观察组患者MLHFQ评分(41.68±3.81)分低于对照组的(52.14±5.25)分,差异具有统计学意义(P<0.05)。治疗后,观察组患者不良事件发生率为10.00%,对照组患者不良事件发生率为6.67%,组间比较差异无统计学意义(P>0.05)。结论诺欣妥联合达格列净能够有效改善射血分数降低心衰患者的心功能情况,提升治疗效果,且对提高患者生活质量具有积极意义,两者联合使用不会增加不良事件的发生风险,具有较好的安全性,值得推广应用。
Objective To explore the therapeutic effect and safety of sacubitril valsartan sodium tablets(trade name:Entresto)combined with dapagliflozin in the treatment of heart failure with reduced ejection fraction(HFrEF).Methods 60 patients with heart failure with reduced ejection fraction were divided into an observation group and a control group according to random numerical table,with 30 patients in each group.The control group received treatment with Entresto,while the observation group received treatment with Entresto and dapagliflozin.Comparison was made on cardiac function[N-terminal pro-brain natriuretic peptide(NT-proBNP),left ventricular ejection fraction(LVEF),left ventricular end-diastolic diameter(LVEDD),6-min walking test(6MWT)distance]after 5 months of treatment,quality of life[Minnesota living with heart failure questionnaire(MLHFQ)score]before and after treatment,incidence of adverse events between the two groups.Results After treatment,the observation group had lower NT-proBNP of(865.47±68.41)pg/ml than(1285.54±105.84)pg/ml in the control group,and shorter LVEDD of(51.47±3.54)mm than(58.65±1.47)mm in the control group,higher LVEF of(48.56±10.65)%than(38.36±5.34)%in the control group,and longer 6MWT distance of(324.02±40.65)m than(226.35±34.91)m in the control group.The difference was statistically significant(P<0.05).After treatment,MLHFQ score in both groups was lower than that before treatment,and MLHFQ score of(41.68±3.81)points in the observation group was lower than(52.14±5.25)points in the control group.The difference was statistically significant(P<0.05).After treatment,the incidence of adverse events was 10.00%in the observation group and 6.67%in the control group,and there was no statistical significance between the two groups(P>0.05).Conclusion The combination of Entresto and dapagliflozin can effectively improve the cardiac function of patients with heart failure with reduced ejection fraction,enhance treatment effect,and have a positive significance in improving the quality of life of patients.The combination of the two does not increase the risk of adverse events and has high safety,which is worth promoting and applying.
作者
章练锋
张卓玲
李绍华
陈奕彬
ZHANG Lian-feng;ZHANG Zhuo-ling;LI Shao-hua(Internal Medicine Department,Puning Overseas Chinese Hospital,Puning 515300,China)
出处
《中国现代药物应用》
2024年第4期21-24,共4页
Chinese Journal of Modern Drug Application
基金
揭阳市卫生健康局医学科学技术研究立项项目(项目编号:揭市卫[2023]42号-74)。
关键词
沙库巴曲缬沙坦钠片
达格列净
射血分数
心力衰竭
预后
Sacubitril valsartan sodium tablets
Dapagliflozin
Ejection fraction
Heart failure
Prognosis
